Evaluation of Electrocardiographic Measurements by High Density Electrode ECG (ECG-HD)

Sponsor
University Hospital, Bordeaux (Other)
Overall Status
Recruiting
CT.gov ID
NCT04921501
Collaborator
(none)
500
1
1
59.8
8.4

Study Details

Study Description

Brief Summary

Cardiac electrical activity is detected on the body surface with conventional electrocardiography involving 12 leads (ECG 12). A limitation of the current ECG technique is that recordings are obtained from only 6 independent precordial leads pairs ; which may miss cardiac potentials from spatially limited regions. More extensive sampling of the body surface may contribute to additional clinical information. The present study investigates the additional sensitivity of ECG using 128 body surface leads (High Density (HD) ECG) in measuring global or regional cardiac activity.

Condition or Disease Intervention/Treatment Phase
  • Device: HD ECG
  • Device: Conventional 12-lead ECG
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
500 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Prospective single arm monocentric descriptive and evaluation study.Prospective single arm monocentric descriptive and evaluation study.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Evaluation of Electrocardiographic Measurements by High Density Electrode ECG (ECG-HD)
Actual Study Start Date :
Apr 6, 2021
Anticipated Primary Completion Date :
Apr 1, 2026
Anticipated Study Completion Date :
Apr 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Proven or suspected arrhythmias group

Device: HD ECG
This experimental procedure is a passive, non-invasive, high-density surface ECG recording using 128 skin electrodes.The electrodes are positioned on strips of 10 electrodes to be prepared with adhesive tape and coated with conductive gel before installation on the patient. The total duration of the acquisition is 10 to 30 minutes.

Device: Conventional 12-lead ECG
This standard 12-lead ECG is defined on the HD ECG, from electrodes F13, G3, G14, H5, H15, H25 corresponding to the precordial electrodes. 4 limb electrodes will be added for the frontal leads. Thus, the HD and 12-lead ECGs will be obtained simultaneously.

Outcome Measures

Primary Outcome Measures

  1. Identification of the "amplitude" electrical criteria by HD ECG [Day 0]

    These electrical criteria are measured in millivolt (mV)

  2. Identification of the "cardiac time" electrical criteria by HD ECG [Day 0]

    Defined by the auricular cardiac time, ventricular depolarization and repolarization time

  3. Identification of the "duration" electrical criteria by HD ECG [Day 0]

    These criteria are measured in milliseconds (ms)

  4. Identification of "anatomical locations" electrical criteria by HD ECG [Day 0]

    Defined by the position of the electrodes

Eligibility Criteria

Criteria

Ages Eligible for Study:
14 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient managed at the Bordeaux University Hospital for assessment of documented severe ventricular arrhythmia (VF, sudden resuscitated death) or suspected (syncope, family history of sudden death, ECG or Holter abnormality) or impaired ventricular conduction, OR

  • Patients managed for prophylactic ventricular defibrillator implantation, according to international recommendations: Heart disease with ejection fraction < 35%, heart disease with sustained ventricular tachycardia, cardiomyopathies with high rhythmic risk,

  • Women of childbearing age with effective contraception.

Exclusion Criteria:
  • patients under 14 years old,

  • pregnant or nursing woman.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bordeaux University Hospital Pessac France 33604

Sponsors and Collaborators

  • University Hospital, Bordeaux

Investigators

  • Principal Investigator: Michel HAÏSSAGUERRE, MD-PhD, University Hospital, Bordeaux

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT04921501
Other Study ID Numbers:
  • CHUBX 2020/59
First Posted:
Jun 10, 2021
Last Update Posted:
Jun 10, 2021
Last Verified:
Apr 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Bordeaux
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 10, 2021